🇺🇸 FDA
Patent

US 11834515

Macrocyclic compounds as proteasome inhibitors

granted A61KA61K38/00A61P

Quick answer

US patent 11834515 (Macrocyclic compounds as proteasome inhibitors) held by Tri-Institutional Therapeutics Discovery Institute, Inc. expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Tri-Institutional Therapeutics Discovery Institute, Inc.
Grant date
Tue Dec 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K38/00, A61P, A61P29/00, A61P31/00